Advertise
Resources
Member, Beacon International Group, Ltd.
U.K.'s Competition and Markets Authority has fined GlaxoSmithKline P.L.C. £37.6 million ($54.4 million) over pay-for-delay deals that delayed sales of cheaper, generic versions of its anti-depressant Seroxat, reported Bloomberg.
GSK conspired with other firms from 2001 to 2004 to make payments totaling more than £50 million to suppliers of generic versions of paroxetine, the CMA said. The CMA has also fined firms including German drugmaker Merck KGaA, Dutch firm Mylan N.V. and Actavis U.K. Ltd. as part of the probe.